We’re changing the game for #ColorectalCancer screening w/ the FDA approval of Shield, our blood test for people age 45+ at average risk. With Shield, we aim to get more people tested & catch more cancers early, when they’re most treatable.
Read more: https://t.co/oQj60CjBfs
𝐌𝐀𝐑𝐊 𝐘𝐎𝐔𝐑 𝐂𝐀𝐋𝐄𝐍𝐃𝐀𝐑🚨
𝙑𝙞𝙨𝙞𝙩 𝙆𝙣𝙤𝙭𝙫𝙞𝙡𝙡𝙚 𝘾𝙤𝙡𝙡𝙚𝙜𝙞𝙖𝙩𝙚⛳️
🗓️ September 8-10
📍Tennessee National Golf Club
Come out and watch the Vols tee it up before the @vol_football home opener.⤵️
➤11:30am tee time - Sept. 8th
➤8:00am tee time - Sept. 9th
Today we announced that our Guardant Reveal liquid biopsy test - the only tissue-free test for the detection of residual and recurrent disease for colorectal cancer - is now available for patients with breast and lung cancers. Read more: https://t.co/v2XaFtpmku
“Leave no gene behind” says @benlevylungdoc@hopkinskimmel. He recommends every patient with late stage non-small lung cancer receive both liquid & tissue biopsies to determine targetable mutations in their tumors and eligibility for targeted therapies #ILCSC21#biomarkertesting
We're pleased to welcome Craig Eagle, MD as our Chief Medical Officer. Dr. Eagle is a respected leader in oncology, with extensive experience driving medical affairs, clinical development, and clinical trial operations at leading pharmaceutical companies.
https://t.co/N3yB2b8RiH
@aubigdaddy@MLB I do not understand why any company would want to alienate half of the country. Does not make business sense to me. We watch sports to escape so why bring politics into it?
We're proud to announce that our Guardant360 CDx #liquidbiopsy test has received the #CEmark for comprehensive tumor mutation profiling across all solid cancers. https://t.co/owIPoM3bX3
We’re excited to launch Guardant Reveal, the first blood-only #liquidbiopsy test for residual disease and recurrence monitoring of early-stage #colorectalcancer patients. #MRD https://t.co/3GsP9X1vgu